Impact of depression and/or anxiety on patients with percutaneous coronary interventions after acute coronary syndrome: a protocol for a real-world prospective cohort study

Yihui Xiao, Wenyuan Li, Juan Zhou, Jie Zheng, Xiaojie Cai, Manyun Guo, Xiang Hao, Zhanyi Zhang, Yan Liu, Zuyi Yuan, Yihui Xiao, Wenyuan Li, Juan Zhou, Jie Zheng, Xiaojie Cai, Manyun Guo, Xiang Hao, Zhanyi Zhang, Yan Liu, Zuyi Yuan

Abstract

Introduction: Acute coronary syndrome (ACS) is one of the leading causes of death. Depression and/or anxiety after ACS is common. Studies from developed countries have reported that the occurrence of anxiety or depression after ACS might increase the risk of cardiovascular events and mortality. However, the results varied, and are limited in developing countries. Therefore, well designed large-scale real-world study is needed to make further clarification. The main objective of this study is to evaluate whether depression or anxiety could affect the prognosis of patients with percutaneous coronary intervention (PCI) post-ACS.

Method and analysis: The study is a prospective, multicentre, cohort study, which will be performed at 12 large hospitals in northwest China and led by the First Affiliated Hospital of Xi'an Jiaotong University. A total of 5000 patients with PCI post-ACS will be enrolled and followed up for 2 years. Their depression and anxiety status will be evaluated with the Patient Health Questionnaire-9 or Generalised Anxiety Disorder-7 Assessment scales during the follow-up. A Cox proportional hazard model will be used to determine if depression/anxiety after PCI increase the risk of cardiovascular events. The impact of antidepression or antianxiety treatment on the cardiac prognosis will be explored as well among the patients with ACS who received the treatment after PCI.

Ethics and dissemination: This study has been approved by the ethics committee of the First Affiliated Hospital of Xi'an Jiaotong University (approval number: XJTU1AF2016LSL-036). The results will be published in research articles or conference papers.

Trial registration number: NCT03057691.

Keywords: acute coronary syndrome; anxiety; depression; major adverse cardiovascular events; percutaneous coronary interventions.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Study flow diagram.

References

    1. Chen W, Gao R, Liu L, et al. . Report for Chinese cardiovascular disease in 2014. Chin Circul J 2015;07:617–22.
    1. Antoniou S, Colicchia M, Guttmann OP, et al. . Risk scoring to guide antiplatelet therapy post-percutaneous coronary intervention for acute coronary syndrome results in improved clinical outcomes. Eur Heart J Qual Care Clin Outcomes 2018;4:283–9. 10.1093/ehjqcco/qcx041
    1. Zimmerman FH, Cameron A, Fisher LD, et al. . Myocardial infarction in young adults: angiographic characterization, risk factors and prognosis (coronary artery surgery study registry). J Am Coll Cardiol 1995;26:654–61. 10.1016/0735-1097(95)00254-2
    1. Meliga E, De Benedictis M, Gagnor A, et al. . Long-term outcomes of percutaneous coronary interventions with stent implantation in patients ≤40 years old. Am J Cardiol 2012;109:1717–21. 10.1016/j.amjcard.2012.01.400
    1. Lautamäki A, Airaksinen KEJ, Kiviniemi T, et al. . Prognosis and disease progression in patients under 50 years old undergoing PCI: the CRAGS (coronary artery disease in young adults) study. Atherosclerosis 2014;235:483–7. 10.1016/j.atherosclerosis.2014.05.953
    1. Liu M-yan, Jiang R-huan, Hu D-yi, et al. . [Emotional disorder in patients with acute or stable coronary heart disease]. Zhonghua Xin Xue Guan Bing Za Zhi 2009;37:904–7.
    1. Feng H-P, Chien W-C, Cheng W-T, et al. . Risk of anxiety and depressive disorders in patients with myocardial infarction: a nationwide population-based cohort study. Medicine 2016;95:e4464 10.1097/MD.0000000000004464
    1. Huffman JC, Celano CM, Januzzi JL. The relationship between depression, anxiety, and cardiovascular outcomes in patients with acute coronary syndromes. Neuropsychiatr Dis Treat 2010;6:123–36. 10.2147/NDT.S6880
    1. Versteeg H, Roest AM, Denollet J. Persistent and fluctuating anxiety levels in the 18 months following acute myocardial infarction: the role of personality. Gen Hosp Psychiatry 2015;37:1–6. 10.1016/j.genhosppsych.2014.11.010
    1. Jiang W, Krishnan RRK, O'Connor CM. Depression and heart disease: evidence of a link, and its therapeutic implications. CNS Drugs 2002;16:111–27. 10.2165/00023210-200216020-00004
    1. van Melle JP, de Jonge P, Spijkerman TA, et al. . Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med 2004;66:814–22. 10.1097/01.psy.0000146294.82810.9c
    1. Lichtman JH, Bigger JT, Blumenthal JA, et al. . Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science Advisory from the American heart association prevention Committee of the Council on cardiovascular nursing, Council on clinical cardiology, Council on epidemiology and prevention, and interdisciplinary Council on quality of care and outcomes research: endorsed by the American psychiatric association. Circulation 2008;118:1768–75. 10.1161/CIRCULATIONAHA.108.190769
    1. Lichtman JH, Froelicher ES, Blumenthal JA, et al. . Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation 2014;129:1350–69. 10.1161/CIR.0000000000000019
    1. Plummer F, Manea L, Trepel D, et al. . Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry 2016;39:24–31. 10.1016/j.genhosppsych.2015.11.005
    1. Kroenke K, Spitzer RL, Williams JBW, et al. . An ultra-brief screening scale for anxiety and depression: the PHQ-4. Psychosomatics 2009;50:613–21. 10.1176/appi.psy.50.6.613
    1. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001;16:606–13. 10.1046/j.1525-1497.2001.016009606.x
    1. Coulter SA, Campos K. Identify and treat depression for reduced cardiac risk and improved outcomes. Tex Heart Inst J 2012;39:231–4.
    1. Joynt KE, Whellan DJ, O'Connor CM. Depression and cardiovascular disease: mechanisms of interaction. Biol Psychiatry 2003;54:248–61. 10.1016/S0006-3223(03)00568-7
    1. Carney RM, Freedland KE. Depression and coronary heart disease. Nat Rev Cardiol 2017;14:145–55. 10.1038/nrcardio.2016.181
    1. Berkman LF, Blumenthal J, Burg M, et al. . Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA 2003;289:3106–16. 10.1001/jama.289.23.3106
    1. Lespérance F, Frasure-Smith N, Koszycki D, et al. . Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA 2007;297:367–79. 10.1001/jama.297.4.367
    1. Teply RM, Packard KA, White ND, et al. . Treatment of depression in patients with concomitant cardiac disease. Prog Cardiovasc Dis 2016;58:514–28. 10.1016/j.pcad.2015.11.003
    1. Taylor CB, Youngblood ME, Catellier D, et al. . Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 2005;62:792–8. 10.1001/archpsyc.62.7.792
    1. Glassman AH, O'Connor CM, Califf RM, et al. . Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002;288:701–9. 10.1001/jama.288.6.701
    1. Cooke MJ, Waring WS. Citalopram and cardiac toxicity. Eur J Clin Pharmacol 2013;69:755–60. 10.1007/s00228-012-1408-1

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel